On November 24, 2021 Nykode Therapeutics (formerly Vaccibody*) (Euronext Growth (Oslo): VACC) reported the execution of a multi-target license and collaboration agreement with Regeneron (Press release, Nykode Therapeutics, NOV 24, 2021, View Source [SID1234596383]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In accordance with the agreement and as described in the initial announcement, the board of directors of Nykode Therapeutics has today resolved to issue 2,255,034 new shares to Regeneron at a price of NOK 79.07 per share, based on a resolution to increase the share capital granted by the annual general meeting on May 5, 2021.

Following registration of the share capital increase related to the share issue, the share capital of Nykode Therapeutics will be NOK 2,895,027.44, divided into 289,502,744 shares, each with a par value of NOK 0.01. *)

Vaccibody AS, which is changing its company name to Nykode Therapeutics AS, has called for an EGM on November 30, 2021, to vote for the approval of the change of its company name from Vaccibody AS to Nykode Therapeutics AS.

On November 24, 2021 Rousselot B.V. and Zerion Pharma ApS reported that they have strengthened their partnership through an extension of an exclusive license agreement entered into in 2019 (Press release, Zerion, NOV 24, 2021, View Source [SID1234598619]). According to the revised license agreement, Rousselot grants Zerion Pharma an exclusive license to exploit the inventions covered by the patent family belonging to international patent application WO 2017/186889. The revision of the license agreement follows the recent grant of a key European Patent No. 17 722 708.9 that is included in the patent family.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The two companies have worked together since 2019 and Rousselot has supported Zerion Pharma in the development of its Dispersome technology platform that enables significant increase in the solubility of otherwise poorly soluble drug compounds for oral administration. Rousselot has explored early variants of the Dispersome technology and has contributed valuable experimental data including results from pharmacokinetic preclinical studies.

The revised license agreement with Rousselot strengthens Zerion Pharma’s position as an innovative and leading supplier of competitive solutions for addressing one of the pharmaceutical industry’s most pressing problems: poor drug solubility.

"The grant of the European Patent marks an important milestone in our efforts to establish a dominating IP position in the field of preparing amorphous drug formulations using proteins as excipients", says Ole Wiborg, CEO of Zerion Pharma. "We have several other patent families protecting the Dispersome technology but the WO 2017/186889 patent family was filed relatively early and covers certain general aspects of the technology that we consider essential to our business", and continues:
"We are delighted to extend and strengthen our partnership with Rousselot that has done an impressive job in demonstrating the usefulness of proteins as excipients for increasing drug solubility and bioavailability. We are very pleased not only with the license grant that secures our IP position in the field but also with the documentation that Rousselot has established during recent years, including proof-of-concept and the comparative advantages of the Dispersome technology in-vivo."
While Zerion Pharma has been granted a broad exclusive license, Rousselot has retained certain rights to exploit the inventions described in WO 2017/186889 within limited fields. Under the terms of the agreement, Zerion Pharma will pay license fees and royalties to Rousselot. The financial terms are not disclosed.

"We are extremely pleased to have extended our license agreement with Zerion whom we consider an upcoming leader in the field of drug formulation and an optimal partner to further develop our contribution to the Dispersome technology", says Sandor Noordermeer, Vice President Global Marketing & Sales at Rousselot. "Back in 2019, we were impressed to see the promising results Zerion had generated with the use of whey proteins to increase drug solubility. The combination of their strong scientific foundation, innovativeness and Zerion’s fierce efforts to develop the company made the choice easy. I am confident that joining forces through collaboration and this license agreement will ensure successful commercialization of the Dispersome technology as state-of-art in the field of drug formulation".

On November 24, 2021 Amgen (NASDAQ:AMGN) reported that it will present at the 2021 Evercore ISI Healthcare Conference at 5:10 p.m. ET on Tuesday, Nov. 30, 2021 (Press release, Amgen, NOV 24, 2021, View Source [SID1234596025]). Rob Lenz, M.D., Ph.D., senior vice president of Global Development at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, as with other selected presentations regarding developments in Amgen’s business given at certain investor and medical conferences, can be accessed on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

On November 23, 2021 GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) (Press release, GlycoMimetics, NOV 23, 2021, View Source [SID1234595972]). Apollomics’ Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study. The Phase 3 clinical trial is part of a randomized, double-blind, placebo controlled, bridging study program that will evaluate the efficacy of uproleselan in combination with chemotherapy, compared to chemotherapy alone, for treating relapsed/refractory AML, in Chinese patients. The trial will enroll approximately 140 adult patients with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Dosing of the first patient in this Phase 3 clinical trial in Greater China is a significant accomplishment for Apollomics and comes quickly on the heels of our recent completion of enrollment in our own pivotal Phase 3 trial evaluating uproleselan in addition to a standard chemotherapy regimen in patients with relapsed/refractory AML," commented Harout Semerjian, GlycoMimetics Chief Executive Officer.

The primary endpoint for the Apollomics Phase 3 trial is overall survival. Secondary outcome measures include the rate and duration of remission, and whether uproleselan could reduce the rate of oral mucositis, a chemotherapy-related side effect. Apollomics expects to conduct this study at approximately 20 blood cancer clinical research centers across China. Additional information on the Phase 3 trial can be found on clinicaltrials.gov (NCT05054543)

On November 23, 2021 Hologic, Inc. (Nasdaq: HOLX) reported that it will showcase its extensive portfolio of breast and skeletal health products, including screening and diagnostics solutions, breast biopsy, and breast cancer treatment and monitoring solutions, at the 107th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 28 to Dec. 2 (Press release, Hologic, NOV 23, 2021, View Source [SID1234595990]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On-site at McCormick Place, in the South Hall in Booth #2511, Hologic will offer attendees opportunities to engage with products, including the Dimensions mammography portfolio, Mach ultrasound systems, and a full suite of breast biopsy and surgery solutions. Additionally, the Company will host a series of both CME and non-CME accredited medical education symposiums and lunch-and-learn sessions, accessible to attendees on-site and from remote locations.

"We’re excited to provide our attendees hands-on experiences with our category-leading innovations, both in our booth and during our medical sessions, as we explore the future of breast health at RSNA 2021," said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. "Our commitment to delivering clinically proven solutions across the continuum of care to improve outcomes, reduce costs and increase patient satisfaction remains steadfast, and we’re ready to bring that commitment to life through our comprehensive programming at this year’s meeting both in-person and virtually."

Medical sessions and symposia taking place throughout the event include:

Clinical Perspective: 3D-Guided Breast Biopsies and Real-Time Specimen Imaging
Harriet B. Borofsky, M.D.
Sunday, Nov. 28: 11:45am – 12:45pm CT
Artificial Intelligence in Breast Imaging (CME)
Sarah (Sally) Friedewald, M.D., FACR
Monday, Nov. 29: 8:00 – 9:00am CT
Options and Tips in Breast Localization
Barry Rosen, M.D., FACS; Colleen M. Madden, M.D.
Monday, Nov. 29: 12:15 – 1:15pm CT
Contrast Enhanced Mammography: Implementation, Application and Biopsy (CME)
Ryan Gabriel, M.D.
Tuesday, Nov. 30: 8:00 – 9:00am CT
Advancing Clinical Excellence with ShearWave Elastography
Priyanka Grover, M.D.
Tuesday, Nov. 30: 12:15 – 1:15pm CT
A New Era of Breast Tomosynthesis: Using High-Resolution Imaging with 3DQuorum Technology
Stamatia V. Destounis, M.D., FACR, FSBI, FAIUM
Wednesday, Dec. 1: 12:15 – 1:15pm CT
For more information on Hologic’s RSNA 2021 offerings or to RSVP for a medical education session, please visit www.HologicVirtual.com.